Se încarcă compania
Just reported
Q3 2026 results
From Rhythm Pharmaceuticals's results release of 3 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
92,1M USD
+80 % y/y
+29 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,61 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-39,3M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Rhythm Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B USDA+
EXELExelixis, Inc.17B USDA+
JAZZJazz Pharmaceuticals plc15,4B USDA
HALOHalozyme Therapeutics, Inc.11,5B USDA+
TECHBIO-Techne Corp11,4B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Situațiile financiare complete →
Construit din raportările proprii ale Rhythm Pharmaceuticals, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
